Bill Moss.jpg

Bill Moss AO

Non Executive Chairman

Bill is an Australian businessman and philanthropist with expertise in healthcare, real estate, banking, funds and asset management.

Bill spent 23 years as a senior executive and Executive Director with Macquarie Group, the pre-eminent Australian investment bank, where he managed The Global Banking and Real Estate businesses.

 

Bill founded, grew and led Macquarie Real Estate Group to a point where it managed over $30 billion worth of investments around the world.

Bill Moss was responsible for creating and building businesses in the areas of real estate investment, property funds management, finance and banking, tourism and leisure, and mortgage banking.

 

At the time of his resignation in December 2006, the business had grown to over 1,400 staff, located in USA, Europe, UK, Japan, China, Hong Kong, Singapore, New Zealand and Australia, which led to one of Macquarie Group’s most profitable businesses.

 

Bill has been a director of eight listed property trusts and one listed infrastructure trust.Bill was the Co-Chair of the Territory 2030 Steering Committee and part of Australia’s 2020 summit.

Bill is a commentator on the Australian finance and banking sectors, the global economy, and the ongoing need for Australia to do more to advance the interests of the country’s disabled and disadvantaged.


Having donated his time over 30 year period to being a Founder, Director and Patron of some fourteen charities and community groups, in 2015, Bill was awarded one of Australia’s highest honours, Office of the Order of Australia (AO), for services to the banking, charity, and finance sectors.

Bill is currently Chairman of the Boston Group of Companies, a diversified investment & development group, as well as being a co-founder and director of Facio Therapies a leading international Biotech company developing therapeutics to treat Facio Scapulo Humeral Muscular Dystrophy (FSHD)

 

Bill is Chairman and Founder of The FSHD Global Research Foundation.

Pete Ratcliffe.jpg

Pete Ratcliffe

Executive Chairman & CEO

Pete has 20 years’ commercial, operations management & advisory experience in global strategic consultancy roles across Europe, the US, Asia & Australia.

He is the founder & Chairman of Agincourt Advisory, a private market advisory firm specializing in diversified alternative assets, pursing opportunistic interests in Private Debt, Real Estate, Private Equity & Venture asset classes.

 

Focusing on a broad range of industries & sectors including Healthcare, Technology, Renewable Energy, Clean / Green Tech, Financial Services & Fintech, Agriculture & Ag Tech, Commercial Realty, Education & Aged Care.

 

Agincourt provides robust portfolio diversification strategies by identifying & responding to special opportunities across divergent asset classes & sectors with low correlation to the volatility of public markets.

Pete is also a director of Agincourt Bio Consulting pty ltd which he founded after working in the global Life Science strategic consultancy arenas in Europe, the US, Asia and Australia.

Agincourt Bio Consulting is a boutique advisory firm, specializing in providing uniquely tailored approaches to partner identification, commercialization strategies and targeted exposure to Investor networks for the Healthcare, Life Science and Medical Device industries.

Agincourt Bio Consulting works with biotech, tier 1 and 2 pharma, medical device and diagnostic clients supporting corporate strategic planning, licensing, strategic business development, alliance management, IP commercialization, capital raising, cross border engagement & joint venture’s taking advantage of the IP appetite from international markets.

Prior to founding Agincourt Pete headed up the Healthcare business within Datamonitor (part of the Informa group), a leading market analyst firm providing strategic research, bespoke consultancy and commercial, strategic and business operations advisory services.

Pete joined Datamonitor in London supporting clients across Europe & the US.

In 2007 returned to Australia to manage the Asia Pacific healthcare operation.

Past roles include Australian Sales Director for Truven Health Analytics, a US healthcare big data and global health economics outcomes provider, acquired by IBM Watson health in 2016 for $2.6 billion usd.

Pete is a board director of The FSHD Global Research Foundation & a member of the          Scientific Committee.

Natalie Cooney.jpg

Natalie Cooney

Board Director

Natalie Cooney is an entrepreneurial philanthropist at heart.

 

Having grown up with FSHD in her family, she is burning to finding treatments and an ultimate cure for FSHD. Her infectious passion, professionalism, expertise in the field and personal story drives her and her team to fight to improve the quality of life for people living with this muscle wasting disease.

Volunteering for the FSHD Global Research Foundation since its establishment, she recently took reign as Managing Director, and in a short period of time has been quick to achieve, innovate and motivate, setting a new tone, pace for research, brand and voice to the award winning charity – changing the culture of giving, bringing transparency and accountability to the sector, and dramatically increasing fundraising and community engagement, expanding world class medical research by 35% within her first year: driven to improve diagnostics, therapeutics and clinical trials for FSHD.

Natalie is managing director of the FSHD Global Research Foundation & a member of the Scientific Committee.

 

“Hope is what drives the community to survive. The community drives me to provide the hope for a cure”

© 2019 BioRegenex Pty Ltd